140 related articles for article (PubMed ID: 38412758)
1. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
[TBL] [Abstract][Full Text] [Related]
2. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
5. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
6. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
Silfverberg T; Zjukovskaja C; Ljungman P; Nahimi A; Ahlstrand E; Dreimane A; Einarsdottir S; Fagius J; Iacobaeus E; Hägglund H; Lange N; Lenhoff S; Lycke J; Mellergård J; Piehl F; Svenningsson A; Tolf A; Cherif H; Carlson K; Burman J
J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):125-133. PubMed ID: 37748927
[TBL] [Abstract][Full Text] [Related]
7. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
8. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
9. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients.
Bertolotto A; Martire S; Mirabile L; Capobianco M; De Gobbi M; Cilloni D
Neurol Ther; 2020 Dec; 9(2):197-203. PubMed ID: 32548740
[TBL] [Abstract][Full Text] [Related]
10. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
11. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience.
Jespersen F; Petersen SL; Andersen P; Sellebjerg F; Magyari M; Sørensen PS; Blinkenberg M
Mult Scler Relat Disord; 2023 Aug; 76():104829. PubMed ID: 37364374
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
13. Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.
Orlewska K; Bogusz K; Podlecka-Piętowska A; Nojszewska M; Markiewicz M; Liwoch R; Orlewski P; Śliwczyński A; Zakrzewska-Pniewska B; Snarski E
Value Health Reg Issues; 2021 Sep; 25():104-107. PubMed ID: 33865219
[TBL] [Abstract][Full Text] [Related]
14. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
Zhukovsky C; Sandgren S; Silfverberg T; Einarsdottir S; Tolf A; Landtblom AM; Novakova L; Axelsson M; Malmestrom C; Cherif H; Carlson K; Lycke J; Burman J
J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):189-194. PubMed ID: 33106366
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
[TBL] [Abstract][Full Text] [Related]
16. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
Front Immunol; 2020; 11():559. PubMed ID: 32328061
[TBL] [Abstract][Full Text] [Related]
17. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
Kvistad SAS; Burman J; Lehmann AK; Tolf A; Zjukovskaja C; Melve GK; Bø L; Torkildsen Ø
J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):844-848. PubMed ID: 35508373
[TBL] [Abstract][Full Text] [Related]
18. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis.
Mohammadi R; Aryan A; Omrani MD; Ghaderian SMH; Fazeli Z
Biologics; 2021; 15():53-59. PubMed ID: 33688164
[TBL] [Abstract][Full Text] [Related]
19. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.
Mariottini A; De Matteis E; Cencioni MT; Muraro PA
Curr Neurol Neurosci Rep; 2023 Sep; 23(9):507-520. PubMed ID: 37589918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
